RE:Looks like best-case predictions are coming trueWas it confirmed that StageZero is one of the PCR testing companies that are suffering backlog, ad/or unprecedented demand for its PCR tests? Would be nice if it is one of those companies, since we were told that they have a daily capacity of 3,000 tests (if I recall correctly). Otherwise we are all just guessing at the revenues.
Significant Covid testing revenues in Q4 would be great to help with operating expenses, but it’s the cancer testing that I most look forward to. Hoping it would at least be between $650k-$1m in Q4.
Regardless, for me personally, I've connected with Matt (COO), and am comfortable that this company will do well in the years ahead. Matt appears to have a level head, and can execute on James' vision, something that James struggled with (at least from my limited POV). Hope to see this on a nice steep upwards movement mid-late 2022.
Cheers!
gojotv! wrote: The unprecedented demand for Covid tests (backlogs reported) will provide that nice, thick, revenue runway for the growth of Aristotle testing and the international deployment of Care Oncology's treatment protocol.
The fact that the "targets" have been reached (or will soon) bodes well for the next financials.
Expect a great New Year's surprise!
Cheers, and Happy Holidays!